1. Home
  2. BOW vs SLS Comparison

BOW vs SLS Comparison

Compare BOW & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bowhead Specialty Holdings Inc.

BOW

Bowhead Specialty Holdings Inc.

HOLD

Current Price

$24.13

Market Cap

734.3M

Sector

Finance

ML Signal

HOLD

Logo SELLAS Life Sciences Group Inc.

SLS

SELLAS Life Sciences Group Inc.

HOLD

Current Price

$4.85

Market Cap

706.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOW
SLS
Founded
2020
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
734.3M
706.7M
IPO Year
2024
2007

Fundamental Metrics

Financial Performance
Metric
BOW
SLS
Price
$24.13
$4.85
Analyst Decision
Buy
Strong Buy
Analyst Count
7
1
Target Price
$32.29
$10.00
AVG Volume (30 Days)
159.7K
5.9M
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
23.26
50.00
EPS
1.59
N/A
Revenue
$551,589,000.00
N/A
Revenue This Year
$21.42
N/A
Revenue Next Year
$19.41
$67.40
P/E Ratio
$15.38
N/A
Revenue Growth
29.58
N/A
52 Week Low
$21.21
$1.26
52 Week High
$41.98
$6.14

Technical Indicators

Market Signals
Indicator
BOW
SLS
Relative Strength Index (RSI) 58.93 52.42
Support Level $23.72 $4.70
Resistance Level $26.17 $5.01
Average True Range (ATR) 0.80 0.33
MACD 0.32 0.02
Stochastic Oscillator 84.62 61.76

Price Performance

Historical Comparison
BOW
SLS

About BOW Bowhead Specialty Holdings Inc.

Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division, which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury, or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity, and hospitality segments, and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.

About SLS SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Share on Social Networks: